-
This study demonstrates that a sequential screening program that provides patients with first-trimester results and offers the option for early invasive testing or additional serum screening in the second trimester can detect 98% of trisomy 21-affected pregnancies. However, such an approach will result in 17% of patients being considered at risk and, hence, potentially having an invasive test.
-
Raloxifene treatment of postmenopausal women with osteoporosis is associated with a lower incidence of estrogen receptor-positive invasive breast cancer.
-
The use of CEE conferred protection against fracture without an increase in breast cancer but with an increased risk of hypertension, stroke, and venous thromboembolism.
-
With the muscle of an international cooperative group research network and expanded collaboration, confirmatory trials have been increasingly contemporaneously launched or provided important data in a timely fashion to help solidify important issues in the care of our patients.
-
Breast Cancer and the Use of Statins; Warnings Issued for IBS Drugs; FDA Actions.
-
-
-
Hormonal replacement therapy after breast canceris It Safe? (HABITS) began in May 1997, to compare breast cancer survivors treated for at least 2 years with hormone therapy with treatment other than hormones. By September 2003, a total of 434 women had been randomized and, in December 2003, the steering committee of the HABITS study made the decision to stop the trial because there were 26 women in the treated group and 7 in the non-treated group with new breast cancer diagnoses.
-
Changes in screening, endocervical sampling, nomenclature, and improvements in treatment likely explain the increased in situ cervical SCC incidence in white and black women. Increasing AIS incidence over the past 20 years in white women has not yet translated into a decrease in invasive AC incidence.
-
In this article, Adams and Nelson integrate results from several disparate fields to advance the concept that autoimmune conditions resemble host vs graft disease and that the graft in many cases may be fetal or maternal cells that lodge in the host, namely the mother or fetus, respectively.